Medication info
Liragenta Duo Extended-release Tablets 5/1000 mg (Linagliptin, Metformin)

Liragenta Duo Extended-release Tablets 5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›6.67mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
This medication is a yellow oval extended-release film-coated tablet.
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401558 · Approved 2024.06.27 · Insurance code 665003350

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to achieve better blood sugar control in conjunction with dietary and exercise regimens. The combination of Linagliptin and Metformin provides stable management of blood glucose levels, leading to favorable therapeutic effects. This improves diabetes management and helps in the prevention of complications.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication consists of two components, Metformin and Linagliptin, and is primarily used in the treatment of type 2 diabetes. While taking this medication, there is a rare risk of developing a dangerous condition called lactic acidosis; therefore, patients with impaired renal or liver function should not take this medication. Patients with type 1 diabetes or serious conditions such as diabetic ketoacidosis, pre-coma, etc., should also avoid using this medication. Patients with acute cardiac conditions, heart failure, severe infections, shock, or acute trauma should avoid taking this medication. Women who are pregnant or planning to become pregnant are advised to avoid using this medication, and breastfeeding women should also refrain from its use for safety. This medication may cause hypoglycemia, so it is particularly important to monitor blood sugar levels carefully when taken alongside insulin or sulfonylureas. Since the Metformin component is excreted by the kidneys, elderly patients with decreased renal function or patients with kidney diseases should undergo regular renal function tests, and dosage adjustments may be necessary as needed. Gastrointestinal disorders may occur, but taking the medication with meals or after meals can help reduce symptoms. If severe abdominal pain, persistent vomiting, diarrhea, muscle weakness, or respiratory difficulties occur while taking this medication, consult a doctor immediately. Additionally, this medication can interact with other drugs, so if other medications are being taken, be sure to inform healthcare professionals. Do not chew or crush this medication; swallow it whole. It is normal for the tablet coating to pass unchanged in the stool, so there is no need for concern regarding this. Serious adverse reactions may include pancreatitis or bullous pemphigoid-like skin reactions, so immediate treatment is required if severe abdominal pain or skin changes occur. It is very important to monitor any adverse reactions and changes in renal function through regular blood tests and physical examinations while taking this medication.

Side effects

Severe lactic acidosis, hypoglycemia, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemia, taste disorder, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulceration, abnormal liver function tests, hepatitis, itching, erythema, rash, pemphigus-like eruptions, severe and disabling arthralgia, rhabdomyolysis, elevated lipase levels, increased amylase, nasopharyngitis, angioedema, angioedema, hypoglycemia, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, decreased appetite, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pneumonia, hyperglycemia, dyspnea, nausea, upper abdominal pain, dizziness, chest discomfort, weakness, osteoarthritis, limb pain, itching, insomnia, depression, hypertension, benign prostatic hyperplasia, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, periodontitis, influenza, rhinitis, upper respiratory infection, dizziness, confusion, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

This medication is a yellow oval extended-release film-coated tablet.

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.